Raxatrigine

Overview

Raxatrigine is a novel analgesic for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia. It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker. It is a peripherally and centrally acting agent that inhibits sodium channels in a state-dependent fashion. It shows selectivity for the Nav1.7 subtype over the other subtypes tested for both the resting and depolarized states. It was developed by Convergence Pharmaceuticals. It received orphan-drug designation from the US Food and Drug Administration in July 2013. It is currently in phase II studies in bipolar depression.

Application

Products > Drug Discovery > Impurities > Nervous System > Raxatrigine and Impurities | Products > Drug Discovery > Inhibitor

Product Information

• Catalog No.: B0084-474126
• CAS No.: 934240-30-9
• Molecular Formula: C18H19FN2O2
• Molecular Weight: 314.35
• Purity: >98%
• Storage: -20°C Freezer
• Solubility: 10 mM in DMSO

Source

Original product source